Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics
Delandistrogene moxeparvovec is an adeno-associated virus (AAVrh74) vector-based gene therapy that delivers a DMD gene transgene encoding an engineered micro-dystrophin protein, which localizes to the sarcolemma of skeletal and cardiac muscle cells. It is studied in Duchenne muscular dystrophy, a disease caused by a mutation in the DMD gene that results in lack of functional dystrophin.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07542314 | Phase 4 | Duchenne Muscular Dystrophy | Recruiting | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →